Biotech · Private company
CatalYm GmbH
Track this companyFree. Adds CatalYm GmbH to your Dealase workspace and tells you when its record changes.
Clinical trials44 recruiting or active
Pipeline programs12From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline12
- Visugromab (CTL-002)Phase 3 · Cancer-associated CachexiaClinicalTrials.gov · fetched Nov 12, 2026
- Carboplatin AUC 5Phase 2 · Metastatic Non-Squamous Non-Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- DocetaxelPhase 2 · Metastatic Non-Squamous Non-Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- LenvatinibPhase 2 · Unresectable or Metastatic Hepatocellular CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- NivolumabPhase 2 · Metastatic Non-Squamous Non-Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- NivolumabPhase 2 · Unresectable or Metastatic Hepatocellular CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- Pembrolizumab 200 mg Q3WPhase 2 · Metastatic Non-Squamous Non-Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- Pemetrexed 500 mg/m^2Phase 2 · Metastatic Non-Squamous Non-Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- VisugromabPhase 2 · Metastatic Non-Squamous Non-Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- Visugromab 6mg/kgPhase 2 · Metastatic Non-Squamous Non-Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- Visugromab RDE (recommended dose for expansion)Phase 2 · Metastatic Non-Squamous Non-Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- Visugromab RDE (recommended dose for expansion)Phase 2 · Unresectable or Metastatic Hepatocellular CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials4
- Visugromab in Cachexia International TrialPHASE2_PHASE3 · RECRUITING · started Apr 16, 2026ClinicalTrials.gov NCT07112196 · fetched Nov 12, 2026
- Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 FailurePHASE2 · RECRUITING · started Mar 19, 2026ClinicalTrials.gov NCT07219459 · fetched Nov 12, 2026
- Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLCPHASE2 · RECRUITING · started Oct 7, 2025ClinicalTrials.gov NCT07246863 · fetched Nov 12, 2026
- Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLCPHASE2 · RECRUITING · started Aug 1, 2025ClinicalTrials.gov NCT07098988 · fetched Nov 12, 2026